中国国际金融股份有限公司 关于苏州泽璟生物制药股份有限公司 部分募投项目子项目变更、金额调整及新增子项目的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为苏州泽璟生 物制药股份有限公司（以下简称"泽璟制药"或"公司"）的保荐机构和持续督导机构，根 据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求（2022 年修订）》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、行 政法规、部门规章及业务规则的要求，对泽璟制药部分募投项目子项目变更、金额调整 及新增子项目的相关事项进行了核查，具体情况如下： 一、募集资金基本情况 （一）2020 年首次公开发行 A 股股票募集资金 根据中国证券监督管理委员会 2019 年 12 月 31 日作出的《关于同意苏州泽璟生物 制药股份有限公司首次公开发行股票注册的批复》（证监许可[2019]2998 号），公司获 准向社会公开发行人民币普通股（A 股）60,000,000 股，每股面值人民币 1 元，发行价 格为每股人民币 33.7 ...

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.1100 | -0.1500 | 26.67 | -0.2400 | | 每股净资产（元） | 4.63 | 6.02 | -23.09 | 2.95 | | 每股公积金(元) | 11.79 | 12.67 | -6.95 | 9.29 | | 每股未分配利润(元) | -8.10 | -7.63 | -6.16 | -7.32 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.68 | 1.08 | 55.56 | 1.08 | | 净利润(亿元) | -0.28 | -0.39 | 28.21 | -0.57 | | 净资产收益率(%) | -2.28 | -2.45 | 6.94 | -7.12 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 12651.23万股，累计 ...

Core Viewpoint - ZaiJing Pharmaceutical reported a revenue of 168 million yuan for the first quarter of 2025, representing a year-on-year growth of 54.87% [1] - The company incurred a net loss of 28.26 million yuan, an improvement from a net loss of 39.49 million yuan in the same period last year [1] Financial Performance - Revenue for Q1 2025: 168 million yuan, up 54.87% year-on-year [1] - Net loss for Q1 2025: 28.26 million yuan, compared to a net loss of 39.49 million yuan in Q1 2024 [1]

泽璟制药公告，2024年营业收入5.33亿元，同比增长37.91%。归属于上市公司股东的净亏损1.38亿元， 去年同期为净亏损2.79亿元。公司2024年度利润分配预案为不派发现金红利，不送红股，不以资本公积 金转增股本。 ...

泽璟制药公告，公司制定《苏州泽璟生物制药股份有限公司未来三年(2025年—2027年)股东回报规 划》。具体内容包括：公司利润分配可采取现金、股票、现金与股票相结合或法律、法规允许的其他方 式。公司在选择利润分配方式时，相对于股票股利等分配方式优先采用现金分红的利润分配方式。根据 公司现金流状况、业务成长性、每股净资产规模等真实合理因素，公司可以采用发放股票股利方式进行 利润分配；公司可以依法发行优先股。当公司存在以下情形之一时，可以不进行利润分配：最近一年审 计报告为非无保留意见或带与持续经营相关的重大不确定性段落的无保留意见、当年末资产负债率高于 70%、当年经营性现金流量净额为负、公司最近一期经审计的归属于母公司股东的净利润为负、公司未 来12个月内有重大资金支出安排、公司认为的不适宜进行利润分配的其他情况。 ...

Core Viewpoint - The China Ocean Medical Care Theme Stock A has experienced a decline of 0.85% on April 17, with a net value of 1.05 yuan, marking a cumulative drop of 1.95% over three consecutive trading days [1] Group 1: Fund Performance - The fund was established in March 2012 with a total size of 564 million yuan and has achieved a cumulative return of 165.78% since inception [1] - As of the end of 2024, the top ten holdings of the fund account for a total of 59.15% of the portfolio [2] Group 2: Holder Structure - As of the end of 2024, institutional investors hold 5.9 million shares, representing 10.54% of the total shares, while individual investors hold 49.8 million shares, accounting for 89.46% of the total [1] Group 3: Fund Management - The current fund manager, Ms. Liang Jingjing, has a master's degree in pharmaceutical chemistry from Peking University and has held various research positions in the pharmaceutical sector before becoming the fund manager [1]

Core Viewpoint - The Sci-Tech Innovation 100 Index (000698) has shown strong performance, with significant increases in both the index and its constituent stocks, indicating a positive market sentiment towards technology companies in the Sci-Tech Innovation Board [3][4]. Performance Summary - As of April 10, 2025, the Sci-Tech Innovation 100 Index rose by 4.56%, with notable gains from stocks such as Shengyi Electronics (688183) up 13.18% and Huazhu High-Tech (688433) up 12.94% [3]. - The Sci-Tech 100 Index ETF (588030) increased by 4.37%, marking its third consecutive rise, with a latest price of 0.93 yuan [3]. - Over the past three months, the ETF has accumulated a rise of 4.44% [3]. Liquidity and Trading Activity - The ETF experienced a turnover rate of 3.81% during the trading session, with a total transaction volume of 229 million yuan [3]. - The average daily trading volume over the past year reached 474 million yuan, ranking first among comparable funds [3]. Fund Growth and Inflows - The ETF's scale increased by 371 million yuan over the past year, placing it second among comparable funds [4]. - In the last two weeks, the ETF's shares grew by 11.4 million, also ranking second among comparable funds [4]. - There has been a net inflow of funds for three out of the last four trading days, totaling 65.72 million yuan, with an average daily net inflow of 16.43 million yuan [4]. Leverage and Returns - The ETF's financing net purchase amount reached 4.0364 million yuan, with a financing balance of 33.2 million yuan as of the previous trading day [4]. - The ETF's net value increased by 11.71% over the past year, with a maximum monthly return of 27.67% since inception [4]. - The ETF has a Sharpe ratio of 1.04 over the past year, indicating strong risk-adjusted returns [4]. Fee Structure and Tracking Accuracy - The management fee for the ETF is 0.15%, and the custody fee is 0.05%, which are the lowest among comparable funds [4]. - The tracking error over the past six months is 0.018%, demonstrating high tracking accuracy compared to similar funds [4]. Index Composition - As of March 31, 2025, the top ten weighted stocks in the Sci-Tech Innovation 100 Index accounted for 23.76% of the index, with Hengxuan Technology (688608) being the highest at 3.11% [6][8].

现将相关情况公告如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 苏州泽璟生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药物临床试验批准通知书》， 注射用 ZG005 与化疗联合用于消化道肿瘤的临床试验获得批准。 本次临床试验获批事项对公司近期业绩不会产生重大影响。由于药品的研发 周期长、审批环节多、研发投入大，容易受到一些不确定性因素的影响，敬请广 大投资者谨慎决策，注意防范投资风险。 证券代码：688266 证券简称：泽璟制药 公告编号：2025-005 苏州泽璟生物制药股份有限公司 关于自愿披露注射用 ZG005 与化疗联用获得 药物临床试验批准通知书的公告 一、药品基本情况 | 药品名称 | 注射用 ZG005 | | --- | --- | | 剂型 | 粉针剂 | | 规格 | 100mg/瓶 | | 申请人 | 苏州泽璟生物制药股份有限公司、上海泽璟医药技术 | | | 有限公司 | | 申请事项 | 境内生产药品注册临床试验 ...

泽璟制药公告，公司于近日收到国家药监局核准签发的《药物临床试验批准通知书》，注射用ZG005与 化疗联合用于消化道肿瘤的临床试验获得批准。ZG005是重组人源化抗PD-1/TIGIT双特异性抗体粉针 剂，为创新型肿瘤免疫治疗生物制品，注册分类为1类，有望用于治疗多种实体瘤。根据公开查询， ZG005是全球率先进入临床研究的同靶点药物之一，目前全球范围内尚未有同类机制药物获批上市。 ...

Summary of the Conference Call on the Pharmaceutical Industry and Policy Trends Industry Overview - The conference call primarily discusses the pharmaceutical industry in China, focusing on recent policy changes and their implications for various companies and market segments [2][3][27]. Key Points and Arguments Policy Changes - Significant changes in the pharmaceutical sector's policies have been noted, particularly regarding the optimization of centralized procurement (集采) and the rapid implementation of commercial health insurance [2][3]. - The government emphasized "optimizing centralized procurement" and "improving the drug pricing mechanism" during the recent National People's Congress, indicating a shift towards a more market-oriented competitive mechanism [2][3]. Impact on Market Valuation - The adjustments in procurement policies are expected to alleviate previous concerns regarding industry valuation suppression, allowing more differentiated and branded products to enter the market [3][4]. - The introduction of a diversified payment system, particularly through commercial health insurance, is anticipated to exceed a market scale of over 1 trillion yuan, providing new payment opportunities for innovative drugs [3][7]. Opportunities for Innovative Drug Companies - Companies like Heng Rui Medicine, BeiGene, and Innovent Biologics are expected to achieve their first or continued profitability, potentially launching significant products [3][9]. - The Chinese biopharmaceutical industry is gaining global recognition, with increasing external licensing collaborations [9]. Emerging Market Segments - The Antibody-Drug Conjugates (ADC) sector, represented by companies like Kelun-Biotech, shows promising performance, while new-generation O-type biologics and T-cell engagers (TCE) are also highlighted for their potential [3][13]. Changes in Health Insurance Policies - The shift in health insurance policies from cost-saving to health prioritization is noted, with a focus on quality regulation and the establishment of drug traceability mechanisms [3][27]. - By the end of 2026, all Diagnosis-Related Group (DRG) systems will be fully implemented, leading to stricter internal cost control in hospitals [5]. Financial Outlook for the Pharmaceutical Industry - The pharmaceutical industry is expected to see a reversal in revenue, profit, and cash flow due to factors such as increased payments from commercial insurance and optimized procurement policies [19][30]. - The overall financial indicators for the industry are projected to improve, driven by both traditional drug revenues and medical devices, particularly high-value consumables [19][30]. Development of Medical Devices - The medical device sector is characterized by low penetration rates in high-value consumables, indicating significant room for growth [17][18]. - Domestic companies like Mindray are gradually rising through technological advancements, despite the market being dominated by international giants [18][21]. Investment Opportunities - The conference highlights several innovative drug companies to watch in 2025, including Heng Rui Medicine, BeiGene, and Innovent Biologics, which are expected to release important clinical data and achieve significant market milestones [11][30]. - The potential for mergers and acquisitions in the medical device sector is noted, with active consolidation expected to attract investor interest [25]. Conclusion - The pharmaceutical industry in China is poised for significant growth and transformation due to favorable policy changes, emerging market opportunities, and the increasing recognition of domestic companies on a global scale [27][30].